Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

NCT03321045 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT03321045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03321045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1
Overall status
Recruiting
Start date
November 21, 2017
Completion date
October 31, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer